Skip to search formSkip to main contentSkip to account menu

paquinimod

Known as: N,5-Diethyl-4-Hydroxy-1-Methyl-2-Oxo-N-Phenyl-1,2-Dihydroquinoline-3-Carboxamide 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

ABR-215757

Broader (1)

Quinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used… 
2018
2018
Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse
Quinoline-3-carboxamides (Q compounds) are immunomodulatory compounds that have shown efficacy both in autoimmune disease and… 
2018
2018
Platelet‐neutrophil interaction aggravates vascular inflammation and promotes the progression of atherosclerosis by activating the TLR4/NF‐κB pathway
Platelet‐neutrophil interaction is well known for its role in inflammatory diseases; however, its biological role in… 
2018
2018
Local S100A8 Levels Correlate With Recurrence of Experimental Autoimmune Uveitis and Promote Pathogenic T Cell Activity
Purpose To investigate the role of damage-associated molecular patterns (DAMPs) in recurrent experimental autoimmune uveitis (EAU… 
2016
2016
Treatment with Quinoline-3-carboxamide does not successfully prevent immune-mediated glomerulonephritis in mice.
2014
2014
FRI0496 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSC) Patients Treated with Paquinimod (ABR-215757)
Background Paquinimod (ABR-215757) is an oral small molecule compound that belongs to the quinoline-3-carboxamide derivatives, a… 
2014
2014
FRI0516 Paquinimod (ABR-215757), an Immunomodulatory Compound, Reduces Fibrosis in the Tight Skin-1 (TSK-1) Model for Systemic Sclerosis
Background Paquinimod (ABR-215757), a new oral small molecular drug, belongs to the quinoline-3-carboxamide derivatives, a class… 
2014
2014
A fusion protein of IL4 and IL10 (IL4-10 synerkine), is very effective in protecting cartilage from blood-induced damage
2014
2014
The S100A9 inhibitor paquinimod (ABR-215757) reduces synovial activation, osteophyte formation and cartilage damage in experimental osteoarthritis
2013
2013
AB0073 The s100a9 inhibitor paquinimod (abr-215757) ameliorates experimental osteoarthritis with high synovial involvement
Background There is increasing evidence that synovial activation contributes to osteoarthritis (OA) pathology and that it is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)